Haloperidol NDC 72205-068

NDC codes

FDA NDC Directory

Product NDC (as listed)72205-068Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72205-0068Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72205-068-91	72205006891	100 TABLET in 1 BOTTLE (72205-068-91)Marketed from Nov 22, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Haloperidol
Generic name (nonproprietary): haloperidol
Active ingredients: Haloperidol — 10 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Novadoz Pharmaceuticals LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 216004
Marketing start: Nov 18, 2022
Listing expires: Dec 31, 2027
Identifiers: Product ID 72205-068_6d0f349d-2354-4358-8fa2-5e35da47eb00SPL ID 6d0f349d-2354-4358-8fa2-5e35da47eb00SPL set ID 3a474e06-fb00-40cb-aa3a-6edad43c2c0aRxCUI 197754, 310670, 310671, 310672, 314034, 314035UNII J6292F8L3DUPC 0372205067912, 0372205064911, 0372205065918, 0372205069916, 0372205065994, 0372205066991, 0372205068919, 0372205064997, 0372205067998, 0372205066915
Pharmacologic class: Typical Antipsychotic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472205006891 followed by a unit qualifier and the quantity

Package 72205-0068-91. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 6, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Haloperidol tablets are indicated for use in the management of manifestations of psychotic disorders. Haloperidol tablets are indicated for the control of tics and vocal utterances of Tourette’s Disorder in children and adults. Haloperidol tablets are effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). Haloperidol tablets are also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 216004

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 216004
Product	Strength	Form · route	Labeler	Product NDC
Haloperidol	Haloperidol 2 mg/1	TabletOral	Novadoz Pharmaceuticals LLC	72205-066
Haloperidol	Haloperidol .5 mg/1	TabletOral	Novadoz Pharmaceuticals LLC	72205-064
Haloperidol	Haloperidol 1 mg/1	TabletOral	Novadoz Pharmaceuticals LLC	72205-065
Haloperidol	Haloperidol 20 mg/1	TabletOral	Novadoz Pharmaceuticals LLC	72205-069
Haloperidol	Haloperidol 5 mg/1	TabletOral	Novadoz Pharmaceuticals LLC	72205-067